How emergency blood-cell production may drive myeloid blood cancers
Emergency Myelopoiesis in the Pathogenesis of Myeloid Malignancies
This work looks at how bursts of emergency myelopoiesis change stem and progenitor cells in people with myeloid blood cancers like AML and MPN to find treatment targets.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11137089 on NIH RePORTER |
What this research studies
This project explores how emergency myelopoiesis — the rapid production of white blood cells during stress or injury — is hijacked in myeloid blood cancers. Researchers will examine hematopoietic stem and progenitor cells from bone marrow and related models to map metabolic and epigenetic changes that drive abnormal self-renewal and blocked maturation. The team will search for molecular vulnerabilities in those pathways that could be targeted with drugs. The approach combines experiments on human samples and laboratory models to connect basic mechanisms with potential therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates would be adults with myeloid malignancies such as acute myeloid leukemia or myeloproliferative neoplasms, or people willing to donate blood or bone marrow samples for research.
Not a fit: People without myeloid or related blood disorders, or those requiring immediate clinical treatment rather than research involvement, are unlikely to receive direct benefit from participation.
Why it matters
Potential benefit: If successful, the project could reveal new drug targets that lead to more effective, less toxic treatments for myeloid blood cancers.
How similar studies have performed: Prior laboratory studies have linked emergency myelopoiesis and stem/progenitor cell changes to myeloid disease, but turning those findings into proven patient therapies is still largely unproven.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Passegue, Emmanuelle — Columbia University Health Sciences
- Study coordinator: Passegue, Emmanuelle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.